Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,756 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00153803 | Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 245 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 6, 2019 | clinicaltrials |
| NCT01953913 | Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation | completed | Phase 3 | 542 | Boehringer IngelheimINDUSTRY | 5 | Aug 12, 2019 | clinicaltrials |
| NCT00300586 | IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 3 | 842 | Hospices Civils de LyonOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT01523587 | LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy | completed | Phase 3 | 795 | Boehringer IngelheimINDUSTRY | 23 | Feb 15, 2019 | clinicaltrials |
| NCT02691299 | A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer(FALUCA) | completed | Phase 3 | 527 | Hutchison Medipharma LimitedINDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02364999 | A Comparative Study Of PF-06439535 Plus Paclitaxel-Carboplatin And Bevacizumab Plus Paclitaxel-Carboplatin Patients With Advanced Non-Squamous NSCLC | completed | Phase 3 | 719 | PfizerINDUSTRY | 27 | Feb 7, 2019 | clinicaltrials |
| NCT00789373 | A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer | completed | Phase 3 | 939 | Eli Lilly and CompanyINDUSTRY | 15 | Dec 14, 2018 | clinicaltrials |
| NCT01121393 | BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 364 | Boehringer IngelheimINDUSTRY | 3 | Dec 14, 2018 | clinicaltrials |
| NCT00805194 | LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer | completed | Phase 3 | 1,314 | Boehringer IngelheimINDUSTRY | 27 | Dec 5, 2018 | clinicaltrials |
| NCT03169335 | Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer | completed | Phase 3 | 535 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 24, 2018 | clinicaltrials |
| NCT02284139 | Pilot Trial of EGF Ointment for the Patients With EGFR-i Related Skin Side Effects | completed | Phase 2 / Phase 3 | 90 | Dong-A University HospitalOTHER | 1 | Apr 23, 2018 | clinicaltrials |
| NCT00949650 | BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | completed | Phase 3 | 345 | Boehringer IngelheimINDUSTRY | 25 | Apr 6, 2018 | clinicaltrials |
| NCT03448146 | A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction | completed | Phase 3 | 90 | PTS International Inc.INDUSTRY | 1 | Feb 28, 2018 | clinicaltrials |
| NCT00364351 | Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy | completed | Phase 3 | 1,574 | Genzyme, a Sanofi CompanyINDUSTRY | 22 | Jan 25, 2018 | clinicaltrials |
| NCT01631136 | Strategies for Maintenance Therapies in Advanced Non Small Cell Lung Cancer | completed | Phase 3 | 932 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Jan 17, 2018 | clinicaltrials |
| NCT00036647 | OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 3 | 731 | OSI PharmaceuticalsINDUSTRY | 17 | Jan 10, 2018 | clinicaltrials |
| NCT01387269 | Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 1) | completed | Phase 3 | 484 | Helsinn Therapeutics (U.S.), IncINDUSTRY | 16 | Oct 27, 2017 | clinicaltrials |
| NCT01387282 | Safety and Efficacy of Anamorelin HCl in Patients With Non-Small Cell Lung Cancer-Cachexia (ROMANA 2) | completed | Phase 3 | 495 | Helsinn Therapeutics (U.S.), IncINDUSTRY | 7 | Oct 27, 2017 | clinicaltrials |
| NCT01351415 | A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 485 | Hoffmann-La RocheINDUSTRY | 18 | Sep 18, 2017 | clinicaltrials |
| NCT02388919 | Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303)(ALTER0303) | completed | Phase 2 / Phase 3 | 439 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 18, 2017 | clinicaltrials |
| NCT01395914 | Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): An Extension Study (ROMANA 3) | completed | Phase 3 | 513 | Helsinn Therapeutics (U.S.), IncINDUSTRY | 17 | Sep 14, 2017 | clinicaltrials |
| NCT00086268 | Non-small Cell Lung Cancer Study US75 (Z-PACT)(ZPACT) | completed | Phase 3 | 250 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 13, 2017 | clinicaltrials |
| NCT01360554 | ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer(ARCHER 1009) | completed | Phase 3 | 878 | PfizerINDUSTRY | 23 | May 24, 2017 | clinicaltrials |
| NCT01999673 | Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer(SUNRISE) | completed | Phase 3 | 582 | Peregrine PharmaceuticalsINDUSTRY | 14 | Apr 21, 2017 | clinicaltrials |
| NCT03117335 | Recombinant Endostatin Combined With Vinorelbine and Cisplatin in Patients With Advanced Non-small Cell Lung Cancer | completed | Phase 3 | 560 | Jiangsu Wuzhong Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01085136 | LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib | completed | Phase 3 | 1,154 | Boehringer IngelheimINDUSTRY | 23 | Apr 4, 2017 | clinicaltrials |
| NCT02044380 | Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 3 | 14 | Boehringer IngelheimINDUSTRY | 1 | Mar 31, 2017 | clinicaltrials |
| NCT02031744 | A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer | completed | Phase 3 | 530 | Hoffmann-La RocheINDUSTRY | 1 | Mar 14, 2017 | clinicaltrials |
| NCT00775385 | TAilored Post-Surgical Therapy in Early Stage NSCLC(TASTE) | completed | Phase 2 / Phase 3 | 152 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT01724801 | Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer(BRAIN) | completed | Phase 3 | 176 | Guangdong Association of Clinical TrialsOTHER | 1 | Mar 1, 2017 | clinicaltrials |
| NCT00806819 | Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC | completed | Phase 3 | 718 | Boehringer IngelheimINDUSTRY | 32 | Feb 2, 2017 | clinicaltrials |
| NCT00349102 | Prevention of Radiation Pneumonitis After Three-dimensional Conformal Radiation Therapy (3D-CRT) in Patients With Non-small-cell Lung Cancer | completed | Phase 3 | 242 | Centre Leon BerardOTHER | 1 | Feb 1, 2017 | clinicaltrials |
| NCT01404260 | Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer(ISCAN) | completed | Phase 3 | 219 | Guangdong Association of Clinical TrialsOTHER | 1 | Jan 27, 2017 | clinicaltrials |
| NCT01351116 | A Trial to Evaluate the Improvement in Lung Cancer Patients Receiving Radiation With or Without Brachytherapy(BRACHY) | completed | Phase 3 | 134 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jan 24, 2017 | clinicaltrials |
| NCT02988635 | Early Palliative Care on Quality of Life of Advanced Cancer Patients | completed | Phase 3 | 281 | Azienda Ospedaliero-Universitaria di ParmaOTHER | 0 | Dec 9, 2016 | clinicaltrials |
| NCT00806923 | A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 1,044 | Hoffmann-La RocheINDUSTRY | 20 | Nov 2, 2016 | clinicaltrials |
| NCT01814553 | ADAM-Afatinib Diarrhea Assessment and Management | completed | Phase 3 | 40 | Boehringer IngelheimINDUSTRY | 1 | Oct 31, 2016 | clinicaltrials |
| NCT00683514 | Oral Chemotherapy And Platinum With Radiotherapy Followed Or Not By Consolidation With The Same Chemotherapy In Locally Advanced Non Small Cell Lung Cancer | completed | Phase 3 | 201 | Pierre Fabre MedicamentINDUSTRY | 1 | Oct 4, 2016 | clinicaltrials |
| NCT00312377 | ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer(ZODIAC) | completed | Phase 3 | 1,690 | Genzyme, a Sanofi CompanyINDUSTRY | 25 | Sep 30, 2016 | clinicaltrials |
| NCT00404924 | ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures | completed | Phase 3 | 1,140 | Genzyme, a Sanofi CompanyINDUSTRY | 22 | Sep 30, 2016 | clinicaltrials |
| NCT00035152 | Study Comparing Weekly Taxol and Carboplatin vs Standard Taxol and Carboplatin Regimen for Stage IIIB or IV Non-Small-Cell Lung Cancer | completed | Phase 3 | 444 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 19, 2016 | clinicaltrials |
| NCT00475098 | Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)(TILT) | completed | Phase 3 | 553 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Sep 2, 2016 | clinicaltrials |
| NCT01887795 | Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study | completed | Phase 3 | 224 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Aug 25, 2016 | clinicaltrials |
| NCT00826683 | Detection of Circulating Endothelial Progenitors Cells (EPCs) in Non-small Cell Lung Cancer (NSCLC)(CBNPC:PCE) | completed | Phase 3 | 140 | University Hospital, LimogesOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00656136 | BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1) | completed | Phase 3 | 585 | Boehringer IngelheimINDUSTRY | 15 | Jul 26, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Sep 6, 2019source: clinicaltrials